Building on More Than 1,000 ScleroSafe® Procedures and Established Clinical Experience in Poland

VANCOUVER, BC, Nov. 4, 2026 /CNW/ -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced a five-year exclusive definitive distribution agreement (the "Agreement") with Calment Medical Sp. z o.o. ("Calment Medical") for the commercialization of ScleroSafe® in Poland, commencing Oct. 15^th 2026. The Agreement includes annual purchase targets representing approximately CAD $1.4 million in aggregate potential purchases over the contractual period, based on the agreed unit pricing and an indicative exchange rate. These targets are subject to the terms of the Agreement and do not constitute guaranteed revenue.

The Agreement appoints Calment Medical as VVT Med's exclusive distributor and importer of ScleroSafe® in Poland and provides a framework for continued commercialization, physician training, and market development. The five-year term is subject to earlier termination in accordance with the Agreement. Actual purchases and revenue will depend on the distributor's performance and other applicable conditions.

The new partnership marks the next phase of VVT Med's commercial activities in Poland, where the Company has already established a meaningful clinical presence. Through the efforts of its previous distribution partner, more than 1,000 ScleroSafe® procedures have been performed in the country to date, alongside the development of a substantial body of clinical experience and supporting evidence.

VVT Med recognizes the important contribution of its previous distributor in establishing the technology in the Polish market, supporting physician adoption, and advancing clinical experience. The transition to Calment Medical is intended to build on this established foundation and support the next stage of commercial development.

"Poland is an important market for VVT Med, with a strong foundation of clinical experience and physician familiarity with ScleroSafe," said Erez Tetro, Chief Executive Officer of VVT Med. "We are grateful to our previous distribution partner for its significant contribution to establishing our technology in the market. With Calment Medical, we look forward to building on this foundation, supporting existing physician relationships, and advancing our commercial activities in Poland."

The agreement forms part of VVT Med's broader European commercialization strategy, which focuses on developing sustainable distribution partnerships, supporting physician adoption, and expanding access to its minimally invasive NT-NT technology across established and emerging markets.

About VVT Med Inc. (VVTM)
VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few FDA-cleared, standalone companies offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe® and V-Block™, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient, and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The Company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038. For more information, visit www.vvtmed.com.

About Calment Medical
Calment Medical Sp. z o.o. is a Poland-based medical device distribution company headquartered in Warsaw. Under the Agreement, Calment Medical will serve as VVT Med's authorized exclusive distributor and importer of ScleroSafe® products in Poland, supporting their commercialization and distribution in the local market.

Cautionary Note Regarding Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements" or "forward-looking information" (collectively, "forward-looking information") under applicable securities laws. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from those anticipated in such statements. Forward-looking information in this news release includes, but is not limited to, statements regarding the achievement of the annual purchase targets, the indicative aggregate value of approximately CAD $1.4 million, the anticipated impact of the Agreement on the Company's commercial presence in Poland, the expected development of the Company's distribution activities through Calment Medical, the potential for continued physician adoption of ScleroSafe®, and the Company's plans to continue expanding its commercial presence in Europe and globally. Such statements reflect the current views of the Company and are not guarantees of future performance. They are based on a number of assumptions, including the Company's ability to execute its business strategy, obtain necessary regulatory approvals, maintain its listing on the TSX Venture Exchange, and continue to develop and commercialize its technologies. Forward-looking information is subject to a variety of risks and uncertainties, including but not limited to: (a) the risk that the distributor may not achieve its purchase targets or that currency fluctuations may affect their Canadian-dollar equivalent; (b) the risk that physician adoption may not develop as anticipated; (c) changes in market conditions or regulatory environments; (d) the need for additional financing, which may not be available on acceptable terms; and (e) general market volatility that may affect the trading price of the Company's securities. The forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change thereafter. Readers are cautioned not to place undue reliance on such information. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT MED INC